Alkermes is a biopharmaceutical company. Co. has a portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO, which utilizes Co.'s proprietary LinkeRx and NanoCrystal technologies; and LYBALVI, which is an oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. We show 56 historical shares outstanding datapoints in our coverage of ALKS's shares outstanding history.
Understanding the changing numbers of ALKS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALKS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALKS by allowing them to research ALKS shares outstanding history
as well as any other stock in our coverage universe. |
Free ALKS Email Alerts:
Video: Shares Outstanding Importance
